Mind Medicine (MindMed) Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDMind Medicine (MindMed) Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 94), indicating clear outperformance against the broad market. Earnings contraction of 22% provides fundamental context to the price action. Investors should exercise caution due to high volatility (64% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $18.47 | +11.99% | ABOVE |
| 50 SMA | $17.69 | +16.97% | ABOVE |
| 100 SMA | $15.30 | +35.24% | ABOVE |
| 150 SMA | $13.94 | +48.37% | ABOVE |
| 200 SMA | $12.63 | +63.82% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MNMD in an uptrend right now?
MNMD has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, MNMD is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is MNMD overbought or oversold?
MNMD's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is MNMD outperforming the market?
MNMD has a Relative Strength (RS) Rating of 94 out of 99. Yes, MNMD is a market leader, outperforming 94% of all stocks over the past 12 months.
Where is MNMD in its 52-week range?
MNMD is trading at $20.69, which is 98% of its 52-week high ($21.09) and 97% above its 52-week low ($6.03).
How volatile is MNMD?
MNMD has a Beta of 1.68 and 52-week volatility of 64%. It's more volatile than the S&P 500 - expect bigger swings.